Northwire Canada EditionMonday, July 13, 2026
Sign inSubscribe
Northwire
⌕
GLDN 0.055 +0.0% BRON 0.040 +0.0% BTO 5.43 −0.7% ESK 0.365 −2.7% AUMN 0.275 +0.0% GGX 0.040 +0.0% S 0.155 +29.2% NNX 0.035 +0.0% ABX 51.90 −0.6% TTS 2.40 −4.0% FCI 0.400 −9.1% GR 0.075 +0.0% AII 23.38 +12.4% TUNG 1.72 +1.8% LGO 1.01 −2.9% EMM 0.080 +0.0% GLDN 0.055 +0.0% BRON 0.040 +0.0% BTO 5.43 −0.7% ESK 0.365 −2.7% AUMN 0.275 +0.0% GGX 0.040 +0.0% S 0.155 +29.2% NNX 0.035 +0.0% ABX 51.90 −0.6% TTS 2.40 −4.0% FCI 0.400 −9.1% GR 0.075 +0.0% AII 23.38 +12.4% TUNG 1.72 +1.8% LGO 1.01 −2.9% EMM 0.080 +0.0%
Management

Rize Oncology Announces Appointment Of Interim CEO

By The Northwire Desk — AI Analysis Oct 16, 2025 · 09:35 RIZE · 0.03 Rize Oncology Inc.
RIZE · Price

Executive Summary

  • Daren Graham resigns as Executive Chairman and interim Chief Executive Officer of Rize Oncology Inc.
  • Board Director P. Gage Jull is appointed as interim Chief Executive Officer pending a permanent selection.
  • The appointment is expected to be temporary while the Board evaluates candidates for the permanent CEO role.

Key Details

  • Daren Graham steps down from both the Executive Chairman and interim CEO positions effective immediately.
  • P. Gage Jull, currently serving as a Director on Rize Oncology’s board, assumes the role of interim Chief Executive Officer.
  • The Board will conduct a search to identify and appoint a permanent Chief Executive Officer; Mr. Jull’s tenure is intended to be limited.
  • No immediate operational or financial impact disclosed beyond the leadership transition.

Notable Quotes

(No direct quotes were provided in the release.)

Read the original news release →

More from Rize Oncology Inc.

Apr 13, 2026 · 16:40

Rize Oncology Announces Warrant Incentive Program

Financings